Dynavax Announces First Quarter 2021 Financial Results
Dynavax Technologies (DVAX) reported a robust first quarter of 2021, achieving total revenues of $83.3 million, a significant increase from $10.9 million in Q1 2020. The company attributed this growth to strong performance from CpG 1018, generating $74.6 million in revenue, while HEPLISAV-B reached $8.3 million despite a decline in vaccine utilization. Notable metrics included an 89.3% seroprotection rate from ongoing clinical trials and a cash position of $232.7 million. The company expects 2021 to be transformational, driven by collaborations and product advancements.
- Total revenue rose to $83.3 million, up from $10.9 million in Q1 2020.
- CpG 1018 revenue reached $74.6 million, significantly contributing to overall growth.
- HEPLISAV-B market share increased to 27% from 21% year-over-year.
- Ongoing clinical trials showed HEPLISAV-B had an 89.3% seroprotection rate.
- HEPLISAV-B revenue declined from $10.5 million in Q1 2020 to $8.3 million in Q1 2021.
EMERYVILLE, Calif., May 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the first quarter of 2021.
"The first quarter of 2021 continued to build on our successful execution in 2020. With the combined strength of opportunities from HEPLISAV-B and CpG 1018, we believe 2021 will be a transformational year for Dynavax," commented Ryan Spencer, Chief Executive Officer of Dynavax. "HEPLISAV-B continues to take market share in accounts targeted by our field sales team, reaching a new high this quarter, which reinforces our belief that it will become the standard of care in the U.S. for adult hepatitis B vaccination."
Mr. Spencer continued, "Dynavax is making progress on numerous collaborations for its proven vaccine adjuvant CpG 1018 across multiple indications, including COVID-19, pertussis, and universal flu. Our COVID-19 collaborations have advanced significantly in recent months with multiple partners targeting emergency or conditional authorization in the second half of 2021. Importantly, these collaborations are now generating significant revenue for Dynavax, with first quarter CpG 1018 revenue of
HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]
- Net product revenue for HEPLISAV-B during the first quarter 2021 was
$8.3 million compared to$10.5 million for the first quarter 2020, driven by increased market share offset by a reduction in vaccine utilization due to the COVID-19 pandemic. - Market share in accounts targeted by the field sales team increased to
27% , up from21% market share in the first quarter of 2020. - Final immunogenicity and interim safety results of the ongoing clinical trial (HBV-24) evaluating HEPLISAV-B in patients undergoing hemodialysis evaluating a new 4-dose regimen of HEPLISAV-B demonstrated a seroprotection rate of
89.3% . Interim safety data showed HEPLISAV-B is well tolerated and no safety concerns were observed. Full safety data are expected by the end of 2021. - Positive results from the post-marketing observational surveillance study (HBV-25) in over 69,000 patients demonstrated the study met the primary endpoint and showed no evidence of an increased risk of acute myocardial infarction associated with vaccination with HEPLISAV-B compared to Engerix-B.
CpG 1018 (Advanced Vaccine Adjuvant)
- Net product revenue for CpG 1018 during the first quarter 2021 was
$74.6 million . - In February, Dynavax initiated a Phase 1 clinical trial of Tdap-1018, its tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine product candidate adjuvanted with CpG 1018.
- In March, Clover Biopharmaceuticals dosed the first participant in SPECTRA, a global Phase 2/3 clinical trial for its trimeric SARS-CoV 2 spike (S) protein vaccine adjuvanted with CpG 1018.
- In April, Valneva reported positive initial results for Part A of the Phase 1/2 clinical trial of its VLA2001 COVID-19 vaccine candidate adjuvanted with CpG 1018 and subsequently initiated a pivotal Phase 3 clinical trial.
- In April, Medigen published positive Phase 1 clinical study data demonstrating neutralizing antibody titers 1.8 to 3.9 times that of human convalescent sera for its COVID-19 vaccine candidate adjuvanted with CpG 1018 and has completed enrollment of over 4,000 participants in its on-going Phase 2 clinical trial.
- In April, CEPI expanded its agreement with the Company to provide funding to manufacture CpG 1018 for its COVID-19 vaccine grantees, increasing total funding under the loan agreement from
$99 million to$176 million .
2021 Milestones
- Multiple data readouts from our CpG 1018 COVID-19 collaboration partners throughout the year
- Data from the ongoing Phase 1 clinical trial of Tdap-1018 in the fourth quarter
- Launch HEPLISAV-B in the EU in the fourth quarter
Financial Results
Total Revenue. Total revenues for the first quarter of 2021 were
Product Revenue, Net. HEPLISAV-B product revenue, net was
Cost of Sales - Product. Cost of sales - product for the first quarter 2021 increased to
Research and Development Expenses (R&D). R&D expenses for the first quarter of 2021 increased to
Selling, General and Administrative Expenses (SG&A). SG&A expenses for the first quarter of 2021 increased to
Income from Operations and Net Income. Income from operations for the first quarter of 2021 was
Cash Position. Cash, cash equivalents and marketable securities totaled
Conference Call and Webcast Information
Dynavax will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at www.dynavax.com. Alternatively, participants may dial (866) 420-4066 or (409) 217-8237 and refer to conference ID 4533398. A replay of the webcast will be available for 30 days following the live event.
Please see Important Safety Information below.
For more information about HEPLISAV-B, visit http://heplisavb.com.
About Hepatitis B
Hepatitis B is a viral disease of the liver that can become chronic and lead to cirrhosis, liver cancer and death. The hepatitis B virus is 50 to 100 times more infectious than HIV,i and transmission is on the rise. There is no cure for hepatitis B, but effective vaccination can prevent the disease.
In adults, hepatitis B is spread through contact with infected blood and through unprotected sex with an infected person. The U.S. Centers for Disease Control (CDC) recommends vaccination for those at high risk for infection due to their jobs, lifestyle, living situations and travel to certain areas.ii Because people with diabetes are particularly vulnerable to infection, the CDC recommends vaccination for adults age 19 to 59 with diabetes as soon as possible after their diagnosis, and for people age 60 and older with diabetes at their physician's discretion.iii Approximately 20 million U.S. adults have diabetes, and 1.5 million new cases of diabetes are diagnosed each year.iv
About HEPLISAV-B
HEPLISAV-B is an adult hepatitis B vaccine that combines hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist CpG 1018 to enhance the immune response. Dynavax has worldwide commercial rights to HEPLISAV-B.
Important U.S. Product Information
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Safety and effectiveness of HEPLISAV-B have not been established in adults on hemodialysis.
For full U.S. Prescribing Information for HEPLISAV-B, click here.
Important U.S. Safety Information (ISI)
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B. Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. The most common patient reported adverse reactions reported within 7 days of vaccination were injection site pain (
Important EU/EEA Product Information
HEPLISAV B is indicated for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
The use of HEPLISAV B should be in accordance with official recommendations.
It can be expected that hepatitis D will also be prevented by immunisation with HEPLISAV B as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
For full EU/EEA. Prescribing Information for HEPLISAV-B, click here.
Important EU/EEA Safety information
Do not receive HEPLISAV B if you have had a sudden life-threatening, allergic reaction after receiving HEPLISAV B in the past, or if you are allergic to any of components of this vaccine, including yeast. Signs of an allergic reaction may include itchy skin, rash, shortness of breath and swelling of the face or tongue.
Appropriate medical treatment and supervision should be readily available in case of rare anaphylactic reactions following the administration of the vaccine.
The administration of HEPLISAV B should be postponed in subjects suffering from acute severe febrile illness.
Immunocompromised persons may have a diminished immune response to HEPLISAV B.
Because of the long incubation period of hepatitis B, it is possible for unrecognised HBV infection to be present at the time of immunisation. HEPLISAV B may not prevent HBV infection in such cases.
There are very limited data on the immune response to HEPLISAV B in individuals who did not mount a protective immune response to another hepatitis B vaccine.
As a precautionary measure, it is preferable to avoid the use of HEPLISAV B during pregnancy. Vaccination during pregnancy should only be performed if the risk-benefit ratio at the individual level outweighs possible risks for the fetus.
The most common patient-reported side effects reported within 7 days of vaccination were pain, swelling or redness at the injection site, feeling tired, headache, muscle aches, feeling unwell and fever.
About CpG 1018 Adjuvant
CpG 1018 is the adjuvant used in HEPLISAV-B. Dynavax developed CpG 1018 adjuvant to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B. CpG 1018 adjuvant provides a well- developed technology and a significant safety database, potentially accelerating the development and large-scale manufacturing of a COVID-19 vaccine.
About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking" statements, including statements regarding the potential for HEPLISAV-B to become the standard of care adult hepatitis B vaccine in the U.S., establishing CpG 1018 as a leading adjuvant, the development of vaccines containing CpG 1018 and potential future sales of CpG 1018, the timing of initiation and completion of clinical studies and the publication of results, the timing of our collaborators seeking emergency use authorization of COVID-19 vaccines containing CpG 1018 adjuvant, our ability to scale manufacturing capacity, the expected demand for our products, our efforts to develop an improved pertussis vaccine, a vaccine for COVID-19, and a universal flu vaccine, entering into strategic relationships and expected results of such relationships, the potential for CpG 1018 to accelerate development and large scale manufacturing of a COVID-19 vaccine and sales potential under certain agreements. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including, the risk that HEPLISAV-B may not become the standard of care adult hepatitis B vaccine in the U.S., risks related to whether and when prescribers and other key decision-makers at potential purchasing entities will make the decision to switch to HEPLISAV-B, and the timing and quantity of actual purchases, risks related to the timing of completion and results of current clinical studies, risks that our collaborators will not get approval of their vaccine candidates, risks related to the development and pre-clinical and clinical testing of vaccines containing CpG 1018, and whether use of CpG 1018 will prove to be beneficial in these vaccines, risks related to whether, when and the quantity of CpG 1018 actually purchased by vaccine companies, risks related to the use of contract manufacturers to supply CpG 1018 and financial commitments made to them, as well as other risks detailed in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.
Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
i CDC. https://www.cdc.gov/hepatitis/hbv/bfaq.htm.
ii CDC. https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm.
iii CDC. https://www.cdc.gov/diabetes/pubs/pdf/hepb_vaccination.pdf.
iv CDC. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-r
DYNAVAX TECHNOLOGIES CORPORATION | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2021 | 2020 | |||||
Revenues: | ||||||
Product revenue, net | $ | 82,885 | $ | 10,514 | ||
Other revenue | 450 | 405 | ||||
Total revenues | 83,335 | 10,919 | ||||
Operating expenses: | ||||||
Cost of sales – product | 24,625 | 2,354 | ||||
Cost of sales - amortization of intangible assets | - | 2,298 | ||||
Research and development | 7,758 | 4,653 | ||||
Selling, general and administrative | 22,423 | 20,926 | ||||
Total operating expenses | 54,806 | 30,231 | ||||
Income (loss) from operations | 28,529 | (19,312) | ||||
Other income (expense): | ||||||
Interest income | 47 | 590 | ||||
Interest expense | (4,712) | (4,731) | ||||
Sublease income | 2,022 | 1,926 | ||||
Change in fair value of warrant liability | (25,552) | 8,610 | ||||
Other | 557 | 322 | ||||
Net income (loss) | $ | 891 | $ | (12,595) | ||
Basic net income (loss) per share | $ | 0.01 | $ | (0.15) | ||
Weighted average shares used to compute basic net income (loss) per share |
112,035 |
85,477 | ||||
Diluted net income (loss) per share | $ | 0.01 | $ | (0.25) | ||
Weighted average shares used to compute diluted net income (loss) per share |
113,469 |
85,648 | ||||
DYNAVAX TECHNOLOGIES CORPORATION
| ||||||||
March 31, | December 31, | |||||||
2021 | 2020 | |||||||
Assets | ||||||||
Cash, cash equivalents and marketable securities | $ | 232,674 | $ | 165,036 | ||||
Inventories, net | 68,846 | 63,689 | ||||||
Property and equipment, net | 30,696 | 30,567 | ||||||
Operating lease right-of-use assets | 25,799 | 26,583 | ||||||
Goodwill | 2,197 | 2,297 | ||||||
Other assets | 129,907 | 65,100 | ||||||
Total assets | $ | 490,119 | $ | 353,272 | ||||
Liabilities and stockholders' equity | ||||||||
Total current liabilities | $ | 109,422 | $ | 77,411 | ||||
Total long-term liabilities | 280,935 | 217,168 | ||||||
Stockholders' equity | 99,762 | 58,693 | ||||||
Total liabilities and stockholders' equity | $ | 490,119 | $ | 353,272 | ||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-announces-first-quarter-2021-financial-results-301285853.html
SOURCE Dynavax Technologies
FAQ
What were Dynavax's total revenues in Q1 2021?
How much revenue did CpG 1018 generate in Q1 2021?
What was the revenue for HEPLISAV-B in Q1 2021?
What are the future prospects for Dynavax in 2021?
What is the net income for Dynavax in Q1 2021?
